Advertisement

Pharmacy World & Science

, 31:565 | Cite as

Changing Clostridium difficile infection testing and treatment trends at a large tertiary care teaching hospital

  • Miguel Salazar
  • Kevin W. GareyEmail author
  • Zhi-Dong Jiang
  • Thanh Dao-Tran
  • Herbert DuPont
Research Article

Abstract

Objective To assess changes in testing and treatment trends of CDI at a time when the Clostridium difficile hypervirulent strain was first identified. Method A retrospective cohort study was performed. C. difficile cytotoxicity results were merged with pharmacy databases and changes in testing and treatment pattern over time were assessed. Results 6,613 tests for C. difficile were performed on 5,100 patients. Using least squares regression times series analysis, rates of testing increased by 0.63 ± 0.31 tests per month (P = 0.05) although the number of positive tests did not increase significantly. Overall, metronidazole was the most commonly used drug (81.6%), followed by vancomycin (9.3%), rifaximin (8.4%), and nitazoxanide (0.70%). Use of rifaximin increased by 3.3 ± 0.55 new prescriptions per month (Fig. 2; P < 0.01) while use of metronidazole increased by 5.0 ± 2.8 new prescriptions per month and oral vancomycin increased by 0.4 ± 0.7 new prescriptions per month; however these results were not statistically significant. For patients receiving rifaximin the drug was given as monotherapy (26.2%), in combination with oral vancomycin (24.2%), or in combination with metronidazole (49.7%). Conclusion Increased rates of CDI testing and use of alternative therapies was observed at a time when the hypervirulent strain was first identified.

Keywords

Antimicrobial treatment C. difficile testing Clostridium difficile Diagnostic tests Diarrhea United States 

Notes

Acknowledgement

Conflicts of interest statement

The authors declare no conflicts of interest associated with the publication of this article.

References

  1. 1.
    Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis. 2004;189(9):1585–9.CrossRefPubMedGoogle Scholar
  2. 2.
    McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Jiang ZD, Garey KW, LaRocco M, DuPont HL. Fecal inflammatory markers and C. difficile genotypes. IDSA annual meeting Oct 4–7, 2007, San Diego, CA.Google Scholar
  5. 5.
    Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16(8):459–77.CrossRefPubMedGoogle Scholar
  6. 6.
    Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther. 2005;3(2):201–11.CrossRefPubMedGoogle Scholar
  7. 7.
    Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother. 2006;40(12):2155–63.CrossRefPubMedGoogle Scholar
  8. 8.
    Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40(11):1586–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44(6):846–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis. 2006;43(4):421–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Barbut F, Depitre C, Delmee M, Corthier G, Petit JC. Comparison of enterotoxin production, cytotoxin production, serogrouping, and antimicrobial susceptibilities of Clostridium difficile strains isolated from AIDS and human immunodeficiency virus-negative patients. J Clin Microbiol. 1993;31(3):740–2.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis. 2008;14(6):929–31.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235(3):363–72.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kyne L, Merry C, O’Connell B, Kelly A, Keane C, O’Neill D. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing. 1999;28(2):107–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Tan ET, Robertson CA, Brynildsen S, Bresnitz E, Tan C, McDonald C. Clostridium difficile-associated disease in New Jersey hospitals, 2000–2004. Emerg Infect Dis. 2007;13(3):498–500.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000–2004. Infect Control Hosp Epidemiol. 2007;28(2):131–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2002;23(3):137–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Peled N, Pitlik S, Samra Z, Kazakov A, Bloch Y, Bishara J. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(4):377–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466–72.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Price MF, Dao-Tran T, Garey KW, Graham G, Gentry LO, Dhungana L, et al. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007;65(1):42–6.CrossRefPubMedGoogle Scholar
  23. 23.
    McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2007;28(2):140–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case-control study of community-associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388–96.CrossRefPubMedGoogle Scholar
  25. 25.
    Thachil J. Overprescribing PPIs: time for a hospital antacid policy on Clostridium difficile. BMJ. 2008;336(7636):109.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Garey KW, Graham G, Gerard L, Dao T, Jiang ZD, Price M, et al. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006;40(6):1030–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Miguel Salazar
    • 1
  • Kevin W. Garey
    • 2
    Email author
  • Zhi-Dong Jiang
    • 3
  • Thanh Dao-Tran
    • 1
  • Herbert DuPont
    • 3
  1. 1.St. Luke’s Episcopal HospitalHoustonUSA
  2. 2.University of Houston College of PharmacyHoustonUSA
  3. 3.University of Texas School of Public HealthHoustonUSA

Personalised recommendations